SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Oppenheimer Lowers Alnylam Price Target to $320 From $350, Keeps Outperform

Oppenheimer lowered its price target on Alnylam Pharmaceuticals to $320 from $350 and maintained its Outperform rating.

ALNY

Related stories